Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Nvidia Corp (NVDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Nvidia Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Nvidia Corp trades at $203.16 (market cap $4.77T). The key difference: Nvidia Corp is far larger — about 1062.4× ACADIA Pharmaceuticals Inc.'s market cap, and Nvidia Corp pays a 0.51% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NVDA | |
|---|---|---|
Market Cap | $4.49B | $4.77T |
Sector | Health | Technology |
52-Week High | $28.06 | $235.75 |
52-Week Low | $20.06 | $160.00 |
Enterprise Value | $3.69B | $4.70T |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NVIDIA (NVDA) trades at $204.08, up 4.36% today, with a bearish technical signal despite recent earnings beats. The stock shows exceptional fundamentals with 62.97% net income margin and 114.29% ROE for 2025. Analyst consensus remains strongly bullish with a $324.95 price target, though technical indicators highlight resistance near $207.
Outlook is positive given AI demand and earnings momentum, but risks include peak AI spending concerns and competition. The stock offers growth potential but faces volatility from technical resistance and market rotation themes noted in recent financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
